Diabetic Nephropathies study: WAL0921
Official title Study of WAL0921 in Patients With Glomerular Kidney Diseases
ClinicalTrials.gov ID: NCT06466135
What this study is testing
What is WAL0921?
WAL0921 is an investigational medicine being studied as a potential treatment for kidney diseases like diabetic nephropathy.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see how safe and effective WAL0921 is, and how it behaves in the body, for people with diabetic kidney disease and rare glomerular kidney diseases.
- Who it's for
- It is looking for adults who have diabetic nephropathy or one of the following: primary focal segmental glomerulosclerosis, treatment‑resistant minimal change disease, primary immunoglobulin A nephropathy, or primary membranous nephropathy.
- What's involved
- Participants will receive either WAL0921 or a placebo through an IV infusion every two weeks, for a total of seven infusions. They will also have regular check‑ups and tests during the study.
- Time commitment
- The study lasts about 16 weeks of infusions plus 24 weeks of follow‑up, with visits every two weeks for the infusions and additional visits for monitoring after the last infusion.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Adults, age 18-75 years
- Diagnosis of one of the following glomerular kidney diseases: diabetic nephropathy; primary focal segmental glomerulosclerosis
- eGFR greater than or equal to 30 mL/min/1.73 m2
You likely can't join if
- Currently pregnant or planning to become pregnant
- History of organ transplantation
- History of alcohol or substance use disorder
- Acute dialysis or acute kidney injury within 6 months of Screening
- Any prior or current medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or...
The study team makes the final eligibility decision.
Where it is enrolling
- Los Angeles, California, United States
- Denver, Colorado, United States
- Tamarac, Florida, United States
- Atlanta, Georgia, United States
- Hinsdale, Illinois, United States
- Dakota Dunes, South Dakota, United States
- Houston, Texas, United States
- San Antonio, Texas, United States
- Westmead, New South Wales, Australia
- St Albans, Victoria, Australia
- Cheras, Kuala Lumpur, Malaysia
- Kuala Lumpur, Kuala Lumpur, Malaysia
- Kuantan, Pahang, Malaysia
- Kajang, Selangor, Malaysia
- Petaling Jaya, Selangor, Malaysia
- Anyang, South Korea
- Busan, South Korea
- Seongnam-si, South Korea
- Seoul, South Korea
- Soeul, South Korea
+ 3 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Los Angeles, California, United States; Denver, Colorado, United States; Tamarac, Florida, United States; Atlanta, Georgia, United States; Hinsdale, Illinois, United States; Dakota Dunes, South Dakota, United States and 17 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.